Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a metabolically stabilized analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). The parent sequence is extended at the C-terminus with Pro-Gly-Pro to increase resistance to enzymatic breakdown. Selank is catalogued in PubChem under CID 11765600 and CAS 129954-34-3; it is sometimes referred to as TP-7.
In the research literature Selank has been studied primarily as a peptide anxiolytic and nootropic. Reported mechanisms center on modulation of GABAergic neurotransmission-gene expression, effects on monoamine and neurotrophin systems, and immunomodulatory activity inherited from its tuftsin origin. Notably, Selank is described as producing anxiolytic-type effects in models without directly binding GABA receptors. This material is supplied strictly for laboratory research and is not intended for human or animal use.
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Experimental studies report that Selank administration alters the expression of numerous genes involved in GABAergic neurotransmission in rodent frontal cortex within about one hour of dosing, and comparative clinical-research literature has described its anxiolytic magnitude as broadly comparable to the benzodiazepine medazepam while additionally showing antiasthenic and mild psychostimulant characteristics. Unlike benzodiazepines, it is reported not to bind GABA receptors directly.
These results originate from in-vitro assays, animal models, and investigational clinical research reported largely in the Russian-language literature; they characterize the compound in research contexts and are not offered as evidence of clinical efficacy or safety for general use.
Selank was developed jointly by the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Research Institute of Pharmacology as a stabilized analog of tuftsin, extending the natural Thr-Lys-Pro-Arg tetrapeptide with Pro-Gly-Pro. It has since served as a widely cited peptide anxiolytic tool compound, also appearing under the designation TP-7.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. Selank is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
